Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties

Full text
Author(s):
Show less -
Knowles, Rebecca B. [1] ; Lawrence, Matthew J. [2, 3] ; Ferreira, Plinio M. [1] ; Hayman, Melissa A. [1] ; D'Silva, Lindsay A. [2, 3] ; Stanford, Sophie N. [2, 3] ; Sabra, Ahmed [2, 3] ; Tucker, Arthur T. [1] ; Hawkins, Karl M. [2, 3] ; Williams, Phylip R. [4] ; Warner, Timothy D. [1] ; Evans, Phillip A. [2, 3]
Total Authors: 12
Affiliation:
[1] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London - England
[2] Swansea Univ, Med Sch, Swansea, W Glam - Wales
[3] ABMU Hlth Board, NISCHR Hemostasis Biomed Res Unit, Swansea, W Glam - Wales
[4] Swansea Univ, Coll Engn, Swansea, W Glam - Wales
Total Affiliations: 4
Document type: Journal article
Source: PLATELETS; v. 29, n. 2, p. 162-170, 2018.
Web of Science Citations: 1
Abstract

Despite the interwoven nature of platelet activation and the coagulation system in thrombosis, few studies relate both analysis of protein and cellular parts of coagulation in the same population. In the present study, we use matched ex vivo samples to determine the influences of standard antiplatelet therapies on platelet function and use advanced rheological analyses to assess clot formation. Healthy volunteers were recruited following fully informed consent then treated for 7 days with single antiplatelet therapy of aspirin (75 mg) or prasugrel (10 mg) or with dual antiplatelet therapy (DAPT) using aspirin (75 mg) plus prasugrel (10 mg) or aspirin (75 mg) plus ticagrelor (90 mg). Blood samples were taken at day 0 before treatment and at day 7 following treatment. We found that aspirin plus prasugrel or aspirin plus ticagrelor inhibited platelet responses to multiple agonists and reduced P-selectin expression. Significant platelet inhibition was coupled with a reduction in fractal dimension corresponding to reductions in mean relative mass both for aspirin plus prasugrel (-35 +/- 16% change, p = 0.04) and for aspirin plus ticagrelor (-45 +/- 14% change, p = 0.04). Aspirin alone had no effect upon measures of clot structure, whereas prasugrel reduced fractal dimension and mean relative mass. These data demonstrate that platelets are important determinants of clot structure as assessed by fractal dimension (d(f)) and that effective platelet inhibition is associated with a weaker, more permeable fibrin network. This indicates a strong association between the therapeutic benefits of antiplatelet therapies and their abilities to reduce thrombus density that may be useful in individual patients to determine the functional relationship between platelet reactivity, eventual clot quality, and clinical outcome. d(f) could represent a novel risk stratification biomarker useful in individualizing antiplatelet therapies. (AU)

FAPESP's process: 14/04478-5 - Interactions of platelet subpopulations and their relevance to anti-platelet therapy
Grantee:Plinio Minghin Freitas Ferreira
Support Opportunities: Scholarships abroad - Research Internship - Doctorate (Direct)